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444Objective: The role of surgery in the multimodal therapy for selected stage IVoligometastatic non–small cell
lung cancer (NSCLC) is still a forum of open discussion.
Methods: We have retrospectively analyzed the records of 53 patients with oligometastatic NSCLC who had
been treated with curative intent in the period January 1997 to May 2010.
Results: The mean age and the male/female ratio were 61 years and 32:21, respectively. A single metastatic
lesion was present in 45 (84.9%) subjects, in 2 patients there were 2 different anatomic sites involved, and in
8 patients there were 2 metastases in the same site. The most common involved sites were brain (39), followed
by adrenal gland (7), bone (3), vertebrae (3), liver (1), and contralateral supraclavicular lymph node (1). Distant
disease was completely resected in 42 patients; 10 patients were treated with exclusive chemotherapy and/or
radiotherapy and 1 with local laser therapy. Twenty-nine patients had been administered concurrent chemora-
diation in a neoadjuvant setting before the surgical treatment at the lung or both sites (primary/distant). The pul-
monary resection was complete (R0) in 42 patients (79.2%). Overall, 1- and 5-year survivals were 73.1% and
24%, respectively (median follow-up, 28 months). Median overall survival, local disease-free survival, and
distant disease-free survival, estimated using theKaplan-Meier method, were respectively 19, 72, and 12months.
After stepwise multivariate analysis, the weight loss (P< .001), the completeness of pulmonary resection
(P ¼ .0019), and, interestingly, the performance of a positron emission tomography–computed tomography
scan in preoperative staging (P ¼ .05) maintained their independent prognostic value as overall survival deter-
minants.
Conclusions: Surgical treatment for selected stage IV NSCLC is feasible and safe. Furthermore, good survival
can be expected in those patients in whom a complete resection of the primary tumor and radical control of the
distant diseases are accomplished. (J Thorac Cardiovasc Surg 2012;144:444-52)In the majority of patients with lung cancer, the disease is
metastatic at the time of diagnosis. According to themost re-
cent data from the American Cancer Society, Surveillance
Health and Policy Research,1 an estimated 221,130 new
cases of lung cancer were expected in 2011, accounting
for about 14% of cancer diagnoses. Historically, metastatic
non–small cell lung cancer (NSCLC) has been labeled as
stage IV with a single class of M1 disease2; in the New
Lung Cancer Stage System3 a certain degree of variability
is described in the M1 status, therefore recognizing a signif-
icant heterogeneity within stage IV:M1a indicates positivity
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The Journal of Thoracic and Cardiovascular Surglesions (in the lung) and M1b indicates positivity for distant
metastases.Within the dismal prognostic setting of stage IV,
the M1b class has a very poor prognosis (1% at 5 years;
overall survival time, 7-11 months). The standard therapeu-
tic approach for stage M1 NSCLC is normally administered
with palliative intent on the basis of the invariably very poor
outcome, consistently independent from the performance
status. Coherently, the common attitude of clinical research
efforts in this subgroup of patients with NSCLC has been
toward the reduction/control of side/detrimental effects of
therapy with specific focus on the quality of life.4 However,
the subgroup of patients with 1 or 2 distant metastases at the
moment of diagnosis and clinical staging (so-called ‘‘oligo-
metastatic’’) probably is encompassed in a prognostic
pattern that is different from that of the diffuse distant dis-
ease.5 Reports from clinical series in which a single brain
or adrenal metastasis has been surgically removed would in-
dicate that, indeed, there is justification for a more aggres-
sive, tentatively curative, therapeutic approach in this
setting.6-8 To the best of our knowledge, very few reports
exist about the surgical treatment of oligometastatic
NSCLCs, regardless of the metastatic site.6,9
The aim of this study is to add knowledge on these subjects
by evaluating the feasibility and efficacy of a treatmentery c August 2012
Abbreviations and Acronyms
CT ¼ computed tomography
D-DFS ¼ distant disease-free survival
ECOG ¼ Eastern Cooperative Oncology Group
FDG ¼ fluorodeoxyglucose
L-DFS ¼ local disease-free survival
LTS ¼ long-term survival
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
Congedo et al General Thoracic Surgerystrategy plannedwith curative intent performed on all sites of
metastatic disease in oligometastatic NSCLCs, in addition to
the radical surgical treatment of the primary tumor. In this
group of patients we aimed at evaluating survival and identi-
fying prognostic factors influencing overall survival and
local and distant recurrence.G
T
SPATIENTS AND METHODS
This is an observational study that does not include any experimental
treatment. The analysis has been realized on prospectively collected data
within the setting of standard clinical practice. Relevant notice has been
provided to local ethical committees. Based on the information available
from the clinical records, demographic and clinical features were
collected and taken into consideration in the statistical analysis.
Follow-up information was obtained from our clinical database and
from the hospital administrative records. All patients had at least 6 months
of follow-up. Patients were censored for either relapse or death. Pretreat-
ment evaluation included patient history, physical examination, lung func-
tion tests, baseline hematochemical tests, and computed tomographic
(CT) scan of the chest, abdomen, and brain. Histologic confirmation
was obtained through standard cytohistology on material from biopsy
specimens obtained during fiberoptic bronchoscopy and/or CT-guided
fine needle aspiration. Nuclear magnetic resonance imaging of the brain
was performed only in nonunivocal cases or to confirm a feature sugges-
tive of metastatic pattern on a CT scan; radiologically suspected N2 dis-
ease was always pathologically proven via mediastinoscopy or
endoscopic/endobronchial ultrasound endoscopy. A bone radionuclide
study was performed in all patients with NSCLC up to the moment
when an 18-fluorodeoxyglucose (FDG) positron emission tomographic
(PET) scan was routinely performed in addition to other standard staging
procedures (as of June 2005). In the preoperative staging, we defined
‘‘oligometastatic’’ disease as a surgically resectable NSCLC primary
tumor with 1 or 2 metastatic lesions that were considered, as well, to
be radically resectable. Inspired by other similar experiences,9 a dedicated
multidisciplinary team composed of medical and radiation therapy oncol-
ogists, pneumonologists, radiologists, anesthesiologists, and thoracic
surgeons established the eligibility criteria; these criteria were (1) local
disease and metastatic lesion confined in 1 or 2 sites, both considered rad-
ically curable; (2) optimal general clinical condition (evaluated as Eastern
Cooperative Oncology Group [ECOG] 0 or 1); (3) no history of other ma-
lignant disease; and (4) age less than 76 years. At the moment of surgery,
all patients had given their informed consent for the use of data for
research purposes, among the other procedures. Surgical criteria were
designated as follows: (1) extent of the resection, no less than lobectomy
(otherwise considered oncologically inadequate); (2) pneumonectomy, in-
dicated only if less extensive resections were deemed inadequate for com-
pleteness; (3) systematic mediastinal lymph node dissection10,11 planned
and performed in all cases; (4) incompleteness of resection/control at theThe Journal of Thoracic and Cametastatic site(s): exclusion from the study. Pathologic stage was assigned
according to the International Staging System for Lung Cancer 19972
and, accordingly, the resection was considered complete if the proximal
resection margins and the highest mediastinal node were microscopically
free of tumor. In the period between January 1997 and December 2010,
a total of 1847 patients underwent major pulmonary resection for NSCLC
at the Department of Thoracic Surgery of Catholic University of Rome,
Italy. Among these, based on the criteria illustrated above, the relevant
data of 53 patients with oligometastatic disease (2.8%) were used for
the purposes of this study. As well, with respect to the surgical and path-
ologic features relevant to the analysis reported herein, we collected data
on (1) the extent of resection, (2) the pathologic staging, (3) the complete-
ness of resection, (4) the type of mediastinal involvement, and (5) the
30-day morbidity and mortality rates. Follow-up was carried out along
standard procedures. Duration of follow-up, survival, and time to first re-
currence were available for all patients. For the purpose of the overall sur-
vival assessment, time 0 (T0) was arbitrarily selected as the date of last
intervention on the primary lung cancer or on the metastatic lesion and
the terminal event (Tend) was death or status for survivors.
Statistical Analysis
Survival curves were obtained using the Kaplan-Meier method. Sur-
vivals were calculated by the Kaplan-Meier method and compared by
the log–rank and the Breslow tests. The independent variables that
were tested in the univariate analysis were as follows: weight loss
(>10% in the last 6 months before treatment), ECOG score, PET–CT,
clinical T stage (0-1 vs 2-4) and clinical N stage (0 vs 1-2), metastatic
site, number of metastatic sites and number of metastatic lesions, type
of treatment for metastatic disease, whole brain radiation, neoadjuvant
therapy, histology, pathologic T stage (0-1 vs 2-4) and pathologic N stage
(0 vs 1-2), surgical completeness, and adjuvant therapy. The univariate
analysis was carried out on Kaplan-Meier curves via the application of
the Breslow and log–rank tests. Three different end points were analyzed:
5-year overall survival (LTS), defined as the percentage of patients alive
at 5 years after the last treatment (on primary or distant site); 5-year local
disease-free survival (L-DFS), defined as the percentage of patients alive
without local recurrence of disease at 5 years after the last treatment (on
primary or distant site); and 5-year distant disease-free survival (D-DFS),
defined as the percentage of patients alive without distant recurrence of
disease at 5 years after the last treatment (on primary or distant site).
All the variables showing a possible association with survival (P< .1)
at the univariate analysis were entered in a multivariate analysis (Cox pro-
portional hazards model) to identify independent prognostic factors. A
backward elimination approach was used to obtain hazard ratios with
95% confidence intervals. SPSS 12.0 software for Windows (SPSS,
Inc, Chicago, Ill) was used to perform the analysis.RESULTS
Preoperative Staging and Metastatic Pattern
Results characteristics of the entire group are reported in
Table 1 and summarized herein: 40 cases of adenocarci-
noma, 8 of squamous cell carcinoma, and 5 of undifferenti-
ated carcinoma. Thirteen patients had ‘‘chest only’’ stage III
disease, of whom 3 had T4 disease (2 patients with a satellite
nodule on the same lobe and 1 patient with pulmonary
artery infiltration). Most of the cases were N0 (39/53,
73.6%); 10 cases were N2 and 4 N1. Sixteen patients (en-
rolled in the study from June 2005) underwent PET–CT
scan at preoperative diagnostic workup evaluation. In all pa-
tients a pathologic uptake of the metastatic lesions was de-
tected. In 45 (84.9%) patients a solitary metastasis wasrdiovascular Surgery c Volume 144, Number 2 445
























Squamous carcinoma 8 (15.1)
Not differentiated 5 (9.4)
One single metastasis 45 (84.9)
Two metastases 8 (15.1)
Metastasis location
Brain 39 (70.9)




Contralateral Supraclavicular node 1 (1.8)
Two sites 2 (3.8)
ECOG, Eastern Cooperative Oncology Group.
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Sdetected and in 8 (15.1%) there were 2 metastatic lesions.
The most common metastatic site was brain (n ¼ 39) fol-
lowed by adrenal gland (n ¼ 8), bone (n ¼ 3), vertebra
(n ¼ 3), contralateral supraclavicular lymph node (n ¼ 1),
and liver (n¼ 1). In particular, among 39 patients with brain
metastases, 29 underwent surgical radical excision, whereas
in the remaining 10 patients we performed radiosurgery in
accordance with the neurosurgeon’s opinion. Moreover,
all the patients (n¼ 8) with adrenal gland metastases under-
went surgery with or without adjuvant therapy; of 3 patients
with bone metastases, 2 underwent a radical bone resection
(1 humeral resection and 1 rib resection performed at the
same time as the NSCLC surgical procedure), whereas in
1 metastatic lesion located in the left anterior iliac spine
we opted for a more conservative treatment (highly confor-
mal irradiation). Similarly, 2 of 3 patients with vertebral
lesions were surgically treated (en bloc vertebral resection
plus reconstruction) and the remaining patient underwent
radiotherapy alone. Finally, both patients with liver446 The Journal of Thoracic and Cardiovascular Surg(n ¼ 1) and contralateral supraclavicular lymph nodal me-
tastases (n ¼ 1) were surgically treated. Only 2 patients
had 2 metastatic sites: a 39-year-old man (liver plus bone)
and a 46-year-old woman (bone plus adrenal).
Treatment Strategy
The patients underwent different therapeutic sequences:
(1) metastasis treatment, neoadjuvant therapy, and lung
surgery in 22 patients (22/53; 41.5%); (2) metastasis treat-
ment and lung surgery in 20patients (20/53; 37.7%); (3) neo-
adjuvant therapy, lung surgery, and metastasis treatment in 7
patients (7/53; 13.2%); and (4) lung surgery and metastasis
treatment in 4 patients (4/53; 7.5%). The multidisciplinary
team, taking into consideration all relevant parameters,
planned the therapeutic schedule. In particular, patients
with brainmetastaseswere treated at the level of the brain be-
fore the lung resection; patients with adrenal gland metasta-
ses, instead, underwent lung resection first (this is done
according to the principle of preserving the adrenocortical
function for the intervention at the level of the lung). A pre-
operative treatment with the double aim of controlling the
disease locally (with ‘‘neoadjuvant’’ intent) and systemically
was performed in 29 (58.6%) subjects. Nineteen patients re-
ceived chemotherapy alone (cisplatin or carboplatin in com-
bination with paclitaxel or etoposide) and 10 patients
(N2 disease) were treated with a combination of chemother-
apy and concurrent radiotherapy.12,13 A significant local
control with consequent clinical downstaging was recorded
in 17 (58.6%) of these 29 patients.
None of the patients who received neoadjuvant therapy
died during the treatment. Therefore, the entire group of
patients (n ¼ 29) was assessable for treatment-related
complications.Toxicitywas generallymild and entirelyman-
ageable without treatment interruption. The most common
encountered significant treatment-related toxicity was mye-
losuppression. Grade 4 toxicity did not develop in any of
them. One patient experienced neurotoxicity, and other 3
treatment-related hospitalizations occurred, 2 for radiation
pneumonitis (grade 3) and 1 for neutropenic fever (grade 3).
Surgical pulmonary resections, pathologic findings, and
postoperative features are summarized in Table 2. In 3
patients pneumonectomy was needed (1 right-sided).
Thirty-day mortality was 1.9% (1/53) (1 case of pulmonary
embolism after right pneumonectomy). Severe complica-
tions occurred in 5 patients (5/53; 9.4%): 3 had pneumonia
with consequent respiratory failure, 1 had pulmonary embo-
lism (after lobectomy), and 1 had severe bleeding that
required reoperation. Minor complications occurred in 11
patients (11/53; 20,8%): 3 had supraventricular arrhyth-
mias (medically treated), 3 had persistent air leak, 3 had
mucus retention (with lobar/sublobar atelectasia treated
with daily bronchial aspirations), 1 had spatial–temporal
disorientation that resolved without specific therapy, and 1
had a wound infection that required repeated medications.ery c August 2012

























Thirty-day mortality 1 (1.9)
Severe complications 5 (9.4)
Mild complications 11 (20.8)
Adjuvant therapy 38 (71.1)
Whole brain irradiation (39) 33 (84.6)
First recurrence pattern (38)
Local 6 (15.8)
Metastasis 30 (78.9)
Local and metastasis 2 (5.3)
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and 19 stage III. In stage III, 15 patients had persistent
mediastinal lymph node disease. In 11 (11/15; 73.3%) the
disease was microscopic and not detectable at preoperative
radiologic evaluation (only 1 of these patients underwent
PET–CT scan in the preoperative evaluation). Finally, 1
patient showed a complete pathologic response to the
preoperative treatment and no neoplastic foci were detected
at final pathologic examination (pathologic stage 0). In 10
patients (10/53; 18,9%), some residual microscopic rem-
nants of the tumor were found on the bronchial resection
margins and/or in the highest mediastinal resected nodes
(R1), whereas a grossly incomplete (R2) resection occurred
in only 1 patient (1/53; 1.9%). Adjuvant therapy was
administered in 38 patients. In particular, all patients with
residual disease and with mediastinal lymph node involve-
ment were treated with chemotherapy and/or radiotherapy
(if this had not been used before pulmonary resection).
Whole brain radiation was applied in 33 of the 39 patients
with brain metastases: 5 patients refused the adjuvant
treatment and 1 was excluded because of neurologic
function.The Journal of Thoracic and CaRecurrence and Long-Term Survivals
The median duration of follow-up was 28 months with
a minimum follow-up of 6 months. Figure 1, A, shows the
Kaplan-Meier survival curve for the entire group (median
overall survival, 19 months). Median L-DFS and D-DFS
were respectively 72 and 12 months (Figure 1, B and C).
At the time of the last follow-up, 30 patients (30/53;
56.6%) had died of disease, 1 (1/53; 1.9%) died of another
cause, 8 (8/53; 15.1%) were alive with disease, and 14 (14/
53; 26.4%) patients were alive with no evidence of disease.Prognostic Factors
Three different Cox regression analyses have been
performed with 3 end points: LTS, L-DFS, and D-DFS
(Table 3). At univariate analysis, clinical and pathologic
staging (cT factor, cN factor, pT factor, and pN factor)
seem to be correlated with overall survival, but this
evidence is not confirmed at the multivariate analysis. Com-
pleteness of resectionwas confirmed as a strong determinant
of survival: the 11 R1/R2 patients (11/53; 20.8%) showed
LTS and L-DFS rates significantly worse than those with
R0 status (Figure 2,A andB). At the same time, the 8 patients
(8/53; 15.1%) who experienced a weight loss over 10% had
a very poor LTS (median survival time of 6 vs 28; P<.001)
and D-DFS (median survival time of 3 vs 16; P<.001) if
compared with the others (Figure 2, C andD). Local control
of disease was heavily influenced by the mediastinal patho-
logic involvement: the Nþ status was a proven prognostic
factor for the L-DFS (Figure 3, A); in this setting we can jus-
tify the role of adjuvant therapy after pulmonary resection
with a clinically significant beneficial impact on the
L-DFS (Figure 3,B). On the other side, the complete control
of the metastatic lesion by surgery (more than with radiation
or chemotherapy), regardless of the site, is safe and effective
and has a beneficial impact on the D-DFS (Figure 3,C). This
is particularly true at the brain level if surgery is followed by
whole brain radiation (Figure 3, D).
Moreover, we found that a significantly lower median
survival time was shown for patients with 2 brain metasta-
ses if compared with median survival of patients with single
brain metastasis (10 months and 26 months, respectively;
Breslow test P ¼ .056; log–rank rest P ¼ .045). Induction
therapy is not a significant prognostic factor in this series,
very probably owing to the characteristics of the study
group (small size, heterogeneous). Interestingly, patients
who underwent PET–CT scan during preoperative workup
evaluation seem to have a better survival than the others in
terms of LTS (log–rank P ¼ .004) and D-DFS (log–rank
P ¼ .015) (Figure 4, A and B).DISCUSSION
The prognosis of metastatic NSCLC is very poor, with
median survival time ranging from 5 to 6 months.14 Thanksrdiovascular Surgery c Volume 144, Number 2 447
FIGURE 1. Survival: Overall survival of the entire cohort of patients (A), local disease-free survival (L-DFS) (B), and distant disease-free survival
(D-DFS) (C). LTS, Long-term survival.
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ments, the rationale for curing patients with metastatic






[HR (95% CI)] P
Univ.
P
Weight loss* P<.001 [8.01 (2.73-23.51)] P<.001 NS
cT stagey P ¼ .036 NS NS
PET–CT scan P ¼ .004 [0.46 (0.12-0.98)]
P ¼ .05
NS
cN stagez NS NS P ¼ .048
Single metastases P ¼ .045 NS P ¼ .003
Site of metastasesx P ¼ .007 NS NS
Surgery for the metastatic
lesion
P ¼ .041 NS NS
Whole brain irradiation NS NS NS
Neoadjuvant Therapy NS NS NS
pT stagejj P ¼ .006 NS NS
pN stage{ P ¼ .030 NS P ¼ .003
Surgical radicality
(no vs yes)
P<.001 [4.75 (1.87-12.10)] P ¼ .001 P<.001
Adjuvant therapy NS NS P ¼ .011
Histology# P<.001 NS P ¼ .012
LTS, Long-term survival; L-DFS, local disease-free survival; D-DFS, distant disease-free
terval; NS, not significant; PET, positron emission tomography;CT, computer tomography.
other sites; jjpT-stage 0-1 vs pT-stage 2-4; {pN0 vs pNþ; #not differentiated vs others.
448 The Journal of Thoracic and Cardiovascular Surgpalliative to curative intent (disease control and survival)
with special attention to the subject’s quality of life.4 More-
over, sporadic case reports and miniseries have reportedL-DFS D-DFS
Multiv.




[HR (95% CI)] P
NS P<.001 [8.67 (2.65-28.40)] P<.001
NS NS NS
NS P ¼ .015 [0.30 (0.09-0.91)] P ¼ .039
NS NS NS
NS NS NS
NS P ¼ .042 NS
NS P<.001 [0.43 (0.19-0.98)] P ¼ .045
NS P ¼ .005 [0.16 (0.03-0.66)] P ¼ .017
NS NS NS
NS P ¼ .015 NS
[0.21 (0.08-0.89)] P ¼ .008 NS NS
[7.43 (2.32-17.62)] P<.001 P<.001 [4.58 (1.76-11.92)] P ¼ .002
[4.62 (1.71-10.83)] P ¼ .003 NS NS
NS P<.001 NS
survival; Univ., univariate; Multiv., multivariate; HR, hazard ratio; CI, confidence in-
*Over 10% in the last 6 months; ycT stage 0-1 vs cT stage 2-4; zcN0 vs cNþ; x brain vs
ery c August 2012
FIGURE 2. Long-term survival (LTS) (A) and local disease-free survival (L-DFS) (B) according with the completeness of resection. Long-term survival
(C) and distant disease-free survival (D-DFS) (D) according to the presence of a weight loss (>10% in the last 6 months before treatment).
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Sgood survival outcomes in oligometastatic stage IV
NSCLCs, and this fact prompted a more aggressive pallia-
tion attitude toward and a curative strategy in this select co-
hort that very probably reflects a less aggressive biologic
behavior.
From the viewpoint of safety, these evidences are con-
firmed by our results on perioperative outcome. Indeed, we
could explain our very rewarding 30-daymortality/morbidity
rates (1.9% and 23.5%, respectively) with the fact that pa-
tients were highly selected and the particular strategy of
carewas supported by an experiencedmultidisciplinary team.
Safety confirmed, our second aim was to evaluate and
confirm evidence from previous reports5-9,15-19 on
prognostic results of surgical treatment in selected
patients with oligometastatic NSCLC. Long-term survival
analysis (overall 1- and 5-year survival figures of 73.1%
and 24%, respectively) (Figure 1, A) seem to suggest that
this strategy of care is effective.
Following the lines of extreme simplification and accord-
ing to the background information as available from the lit-
erature, we could divide the oligometastatic NSCLCs into 3
groups: (1) cranial, (2) adrenal, and (3) extracranial/extra-
adrenal. This classification, previously reported by Luke-
tich,15 Khan,9 and their associates, reflects the typical
pattern of distant involvement in oligometastatic NSCLC
(brain and adrenal the most common).The Journal of Thoracic and CaBrain
The brain is the most common site of metastasis from
NSCLC, and, in the absence of treatment, the overall
median survival fromdiagnosis is 1 to2months.16 So far there
is no consensus on the standard therapeutic approach regard-
ing primary tumor in patients with synchronous single brain
metastasis from NSCLC; in fact, the distant lesion is to be
controlled with radical intent (by surgery and or stereotactic
radiation therapy). The real usefulness of the combined surgi-
cal approach has been analyzed by several groups, mostly in
single center (sporadically in the multicenter setting) retro-
spective studies. In addition to the analysis of the survival
and quality of life outcomes, authors have constantly focused
their speculation on picking up and validating selection crite-
ria in the preoperative workup to identify the best candidates
for this sort of treatment, indeed aggressive and therefore jus-
tifiable only in the light of a significant improvement of prog-
nosis. These studies are detailed in Table 4.18,20-25
Adrenal
The detection of a single adrenal metastasis is less fre-
quent than that at the level of the brain, and its incidence
is evaluated to be 1.6% to 4% of resectable NSCLCs19,26;
as in the case of the brain, the treatment of adrenal
metastasis in patients in whom complete lung resection
can be accomplished is still a debated issue. Severalrdiovascular Surgery c Volume 144, Number 2 449
FIGURE 3. Prognostic factors after multimodal treatment for oligometastatic; pathologic N status (A) and adjuvant therapy (B) are related to local disease-
free survival (L-DFS) whereas the choice of surgical resection of the distant metastases (C) and the execution of whole brain radiation (D) seem to signif-
icantly influence the distant disease-free survival (D-DFS).
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NSCLC with single adrenal metastasis is feasible and
occasionally associated with satisfactory long-term sur-
vival.21,25,27,28 In the past decade several case series of
adrenal resection for NSCLC metastases have been
evaluated (details in Table 4) with some rewarding results
in terms of long-term survival.FIGURE 4. The prognostic role of fluorodeoxyglucose positron emission to
survival (LTS) (A) and distant disease-free survival (D-DFS) (B).
450 The Journal of Thoracic and Cardiovascular SurgOther Sites
Other sites are described in rare surgical series (pan-
creas,29 pectoralis muscle,30 and leg muscle,31 one of the
largest being that described by Luketich and associates,15
who reported on a group of long-term surviving patients
with single extra-adrenal extracranial metachronous metas-
tasis from surgically resected NSCLC. Similarly, Khan andmographic–computed tomographic (PET–CT) scan: impact on long-term
ery c August 2012





(lung resection) Mortality Morbidity LTS
Prognostic
factors
Billing (2001)20 28 Brain metastases 100% 0% 21.4% 21.4% N0
Porte (2001)21 43 Adrenal metastases 95% 0% 18.6% 14% (3 y) None
Bonnette (2001)22 103 Synchronous brain
metastases
78% 1.9% NR 11% Adenocarcinoma
N0
T1
Granone (2001)18 30 Brain metastases 90% 0% 0% (major complications) 14% (3 y) N0
Adenocarcinoma





Mercier (2005)24 23 Adrenal metastases
(radical lung
resection)
— 0% 13% 23% DFI>6 mo
Tanvetyanon
(review, 2008)25
114 Adrenal metastases 82% 0% 13%-24% 25% Metachronous
metastases
Our series (2012) 53 Various sites 79.2% 1.9% 23.5% 24% R0
Weight loss
PET–CT
LTS, Long-term survival; NR, not reported; CEA, carcinoembryonic antigen; DFI, disease-free interval; PET, positron emission tomography; CT, computed tomography.
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be applied in a class of oligometastatic patients with good
performance status and limited weight loss in attempt to
control all known sites of disease.
Considering all the pertinent literature as reported above,
we can affirm that oligometastatic lung cancer (whatever
the site of the metastatic disease) is a still a forum of
open discussion. In fact, most of the mentioned reports
concluded that combined surgical therapy was the best
treatment and probably the gold standard for these selected
patients, although the identification of prognostic factors
influencing survival remains unclear and the question
‘‘who will benefit from aggressive therapy’’ is unan-
swered.32 We are aware that the present study has the usual
limitations of other retrospective monocentric studies
(the long duration of patient inclusion and the limited num-
ber of patients). Nevertheless, this is one of the largest sur-
gical series of patients with oligometastatic NSCLC with
different metastatic sites involved, consecutively treated
in a single center. Unlike previous works, all patients en-
rolled received a complete treatment of both the metastatic
lesions (all synchronous at the diagnosis) and the primary
pulmonary lesion. Our indications are still not strong
enough to support the outlining of guidelines for specific
situations because of the great variety of factors (preopera-
tive stage, site of metastasis, modality of metastatic
treatment).The Potential Role of PET–CT/FDG
One possible solution to this enigma is a screening ap-
proach realized through the execution of a PET–CT/FDGThe Journal of Thoracic and Caof oligometastic patients to rule out those erroneously la-
beled as such.Very recently, dePas and colleagues33 havehy-
pothesized that this subset of NSCLC patients (PET–CT/
FDG screened) could represent a well-defined population
that would indeed benefit from amore aggressive therapeutic
strategy than that in the same class of disease but stagedwith-
out FDG–PET. In our experiencewe have observed, interest-
ingly, that a comprehensive staging process, with PET–CT/
FDG, could significantly affect the long-term prognosis of
this particular class of patients.CONCLUSIONS
We can assume that, despite the absence of clear
evidence-based guidelines, surgery in highly selected pa-
tients with oligometastatic NSCLC represents a feasible,
safe, and effective option. In particular, the presence of a sin-
gle metastasis diagnosed by PET–CT scan, the absence of
weight loss of more than 10%, the completeness of resec-
tion, and pathologic N0 status were found to be positive
predictive factors for long-term outcome. Further investiga-
tions are mandatory to clearly confirm and evaluate the
real impact of PET–CT scan evaluation on long-term sur-
vival in such patients, although specific prospective ran-
domized analysis on a large series of patients is extremely
controversial.References
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